Patents by Inventor Teodozyj Kolasa

Teodozyj Kolasa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20030225276
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: April 17, 2003
    Publication date: December 4, 2003
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Benzimidazoles that are useful in treating sexual dysfunction
    Publication number: 20030162790
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: September 6, 2002
    Publication date: August 28, 2003
    Inventors: Marlon D. Cowart, Pramila A. Bhatia, Jerome F. Daanen, Andrew O. Stewart, Meena V. Patel, Teodozyj Kolasa, Jorge D. Brioni, Jeffrey Rohde, Kenneth M. Engstrom
  • 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
    Publication number: 20030073850
    Abstract: Compounds of formula I 1
    Type: Application
    Filed: February 17, 2000
    Publication date: April 17, 2003
    Inventors: Robert J. Altenbach, Michael D. Meyer, James F. Kerwin, Albert Khilevich, Teodozyj Kolasa, Jeffrey Rohde, William A. Carroll, Xenia Searle, Fan Yang
  • Benzimidazoles that are useful in treating sexual dysfunction
    Publication number: 20030008878
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: June 5, 2001
    Publication date: January 9, 2003
    Inventors: Marlon D. Cowart, Pramila A. Bhatia, Jerome F. Daanen, Andrew O. Stewart, Meena V. Patel, Teodozyj Kolasa, Jorge D. Brioni
  • Imidazoles and related compounds as &agr;1A agonists
    Patent number: 6503935
    Abstract: Compounds having formula I: are useful in treating diseases prevented by or ameliorated with &agr;1A agonists. Also disclosed are &agr;1A agonist compositions and a method of activating &agr;1 adrenoceptors in a mammal.
    Type: Grant
    Filed: July 29, 1999
    Date of Patent: January 7, 2003
    Assignee: Abbott Laboratories
    Inventors: Robert J. Altenbach, Michael D. Meyer, James F. Kerwin, Jr., Mark W. Holladay, Albert Khilevich, Teodozyj Kolasa, Jeffrey Rohde, William A. Carroll
  • Use of alpha- 1- alpha adrenoceptor agonists with alpha-1-Beta antagonism for the treatment of stress urinary incontinence
    Publication number: 20020183357
    Abstract: The following disclosure relates to a method of treating incontinence with a compound having a specific &agr;1A adrenoceptor profile.
    Type: Application
    Filed: February 17, 2000
    Publication date: December 5, 2002
    Inventors: Jorge D. Brioni, Michael E Brune, Steven A Buckner, Teodozyj Kolasa, James P Sullivan
  • Benzimidazoles that are useful in treating sexual dysfunction
    Publication number: 20020169167
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: March 8, 2002
    Publication date: November 14, 2002
    Inventors: Marlon D. Cowart, Pramila A. Bhatia, Jerome F. Daanen, Andrew O. Stewart, Meena V. Patel, Teodozyj Kolasa, Jorge D. Brioni, Jeffrey Rohde
  • Benzimidazoles that are useful in treating sexual dysfunction
    Publication number: 20020169166
    Abstract: The present invention relates to the use of compounds of formula (I) 1
    Type: Application
    Filed: December 14, 2001
    Publication date: November 14, 2002
    Inventors: Marlon D. Cowart, Pramila A. Bhatia, Jerome F. Daanen, Andrew O. Stewart, Meena V. Patel, Teodozyj Kolasa, Jorge D. Brioni, Jeffrey Rohde
  • Sulfonylphenylpyrazole compounds useful as COX-2 inhibitors
    Patent number: 6472416
    Abstract: The present invention encompasses novel sulfonylphenylpyrazole compounds useful in the treatment of cyclooxygenase-2 mediated diseases.
    Type: Grant
    Filed: August 25, 2000
    Date of Patent: October 29, 2002
    Assignee: Abbott Laboratories
    Inventors: Teodozyj Kolasa, Meena V. Patel
  • Use of selective dopamine D4 receptor agonists for treating sexual dysfunction
    Publication number: 20020103105
    Abstract: The present invention relates to the use of selective dopamine D4 receptor agonists and to compositions containing selective dopamine D4 receptor agonists for the treatment of sexual dysfunction.
    Type: Application
    Filed: November 7, 2001
    Publication date: August 1, 2002
    Inventors: Jorge D. Brioni, Teodozyj Kolasa, Gin C. Hsieh, Diana L. Donnelly-Roberts
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20020028938
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: May 31, 2001
    Publication date: March 7, 2002
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Publication number: 20020013318
    Abstract: The present invention describes pyridazinone compounds of formula I 1
    Type: Application
    Filed: May 31, 2001
    Publication date: January 31, 2002
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Use of &agr;1A adrenoceptor agonists with &agr;1B and &agr;1D antagonism for the treatment of stress urinary incontinence
    Patent number: 6323231
    Abstract: The following disclosure relates to a method of treating incontinence with a compound having a specific &agr;1A adrenoceptor profile.
    Type: Grant
    Filed: February 16, 2001
    Date of Patent: November 27, 2001
    Assignee: Abbott Laboratories
    Inventors: Jorge D. Brioni, Michael E. Brune, Steven A. Buckner, Teodozyj Kolasa, James P. Sullivan
  • Use of alpha1A adrenoceptor agonists with alpha1B and alpha1D antagonism for the treatment of stress urinary incontinence
    Publication number: 20010039255
    Abstract: The following disclosure relates to a method of treating incontinence with a compound having a specific &agr;1A adrenoceptor profile.
    Type: Application
    Filed: February 16, 2001
    Publication date: November 8, 2001
    Inventors: Jorge D. Brioni, Michael E. Brune, Steven A. Buckner, Teodozyj Kolasa, James P. Sullivan
  • Prostaglandin endoperoxide H synthase biosynthesis inhibitors
    Patent number: 6307047
    Abstract: The present invention describes pyridazinone compounds of formula I which are cyclooxygenase (COX) inhibitors, and in particular, are selective inhibitors of cyclooxygenase-2 (COX-2). COX-2 is the inducible isoform associated with inflammation, as opposed to the constitutive isoform, cyclooxygenase-1 (COX-1) which is an important “housekeeping” enzyme in many tissues, including the gastrointestinal (GI) tract and the kidneys. The selectivity of these compounds for COX-2 minimizes the unwanted GI and renal side-effects seen with currently marketed non-steroidal anti-inflammatory drugs (NSAIDs).
    Type: Grant
    Filed: October 27, 1999
    Date of Patent: October 23, 2001
    Assignee: Abbott Laboratories
    Inventors: Lawrence A. Black, Anwer Basha, Teodozyj Kolasa, Michael E. Kort, Huaqing Liu, Catherine M. McCarty, Meena Patel, Jeffrey J. Rohde, Michael J. Coghlan, Andrew O. Stewart
  • Iminoxyderivatives of fenamates as inhibitors of prostaglandin biosynthesis
    Patent number: 5863946
    Abstract: Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; X is absent or is alkylene; A is absent or is selected from optionally substituted alkylene, optionally substituted cycloalkylene, optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, optionally substituted alkenylene, and ##STR2## or R.sup.2 and A together define a saturated 5- to 8-membered optionally substituted carbocyclic or heterocyclic ring to which the group Z is attached; Z is selected from (a) hydrogen, (b) COM wherein M is selected from the group consisting of --OR.sup.5, a pharmaceutically acceptable cation, --NR.sup.7 R.sup.8, and a pharmaceutically acceptable, metabolically cleavable group, (c) --OR.sup.3, (d) tetrazolyl, (e) --CH(OR.sup.3)--CH.sub.2 OR.sup.9, (f) --CH(OR.sup.3)--CH.sub.2 --CH.sub.2 OR.sup.9, (g) --CH(OR.sup.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: January 26, 1999
    Assignee: Abbott Laboratories
    Inventors: Clint D. W. Brooks, Richard A. Craig, Teodozyj Kolasa, Andrew O. Stewart
  • Symmetrical bis-heteroarylmethoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
    Patent number: 5843968
    Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d) --NR.sup.6 SO.sub.2 R.sup.
    Type: Grant
    Filed: October 27, 1997
    Date of Patent: December 1, 1998
    Assignee: Abbott Laboratories
    Inventors: Clint D. W. Brooks, Pramila Bhatia, Teodozyj Kolasa, Andrew O. Stewart, David E. Gunn, Richard A. Craig
  • Oxime derivatives of fenamates as inhibitors of prostaglandin biosynthesis
    Patent number: 5840758
    Abstract: Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; A is selected from (a) optionally substituted alkylene, (b) optionally substituted cycloalkylene, (c) optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, (d) optionally substituted alkenylene and (e) ##STR2## X is absent or is alkylene; Z is selected from (a) hydrogen, (b) COM wherein M is selected from --OR.sup.4, --NR.sup.6 R.sup.7, and a pharmaceutically acceptable metabolically cleavable group, (c) --OR.sup.2, (d) tetrazolyl, (e) --CH(OR.sup.2)--CH.sub.2 OR.sup.8, (f) --CH(OR.sup.2)--CH.sub.2 --CH.sub.2 OR.sup.8, (g) --CH(OR.sup.2)--CH(OR.sup.8)--CH.sub.2 OR.sup.9, and (h).dbd.N--OR.sup.2 ; and R.sup.
    Type: Grant
    Filed: June 6, 1996
    Date of Patent: November 24, 1998
    Assignee: Abbott Laboratories
    Inventors: Clint D. W. Brooks, Teodozyj Kolasa, Wendy Lee, Andrew O. Stewart
  • Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
    Patent number: 5795900
    Abstract: Compounds having the formula: ##STR1## wherein W is the same at each occurrence and is selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted pyridyl, optionally substituted pyrimidyl, and optionally substituted thiazolyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is a valence bond or is selected from hydrogen and alkyl; X is a valence bond or is selected from alkylene, alkenylen, and alkynylene; and Z is selected from (a) COM, (b) CH.dbd.N--O--A--COM, (c) CH.sub.2 --O--N.dbd.A--COM wherein A is selected from alkylene and cycloalkylene, and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.6, (c) --NR.sup.7 R.sup.8, (d)--NR.sup.6 SO.sub.2 R.sup.
    Type: Grant
    Filed: September 17, 1996
    Date of Patent: August 18, 1998
    Assignee: Abbott Laboratories
    Inventors: Clint D. Brooks, Pramila Bhatia, Teodozyj Kolasa, Andrew O. Stewart, David E. Gunn, Richard A. Craig
  • Heteroarylmethoxyphenylthioalkyl carboxylates as inhibitors of leukotriene biosynthesis
    Patent number: 5783586
    Abstract: Compounds having the formula: ##STR1## wherein W.sup.1 and W.sup.2 are independently selected from optionally substituted quinolyl, optionally substituted benzothiazolyl, optionally substituted benzoxazolyl, optionally substituted benzimidazolyl, optionally substituted quinoxalyl, optionally substituted naphthyl; R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, halolalkyl, alkoxy, halogen; R.sup.3 is selected from thienyl, furyl, phenyl, naphthyl, benzo?b!thienyl, alkyl, hydroxyl, and hydrogen; Y an alkylene of one to six carbon atoms; and M is selected from (a) a pharmaceutically acceptable metabolically cleavable group, (b) --OR.sup.4, (c) --NR.sup.5 R.sup.6, (d)--NR.sup.4 SO.sub.2 R.sup.7 (e)--NH--Tetrazolyl, and (f) glycinyl; inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states. Also disclosed are leukotriene biosynthesis inhibiting compositions and a method of inhibiting leukotriene biosynthesis.
    Type: Grant
    Filed: October 1, 1996
    Date of Patent: July 21, 1998
    Assignee: Abbott Laboratories
    Inventors: Teodozyj Kolasa, Clint D. W. Brooks, David E. Gunn